FDA to Review [Vic-]Trastuzumab Duocarmazine for HER2-Positive BRCA
The FDA has accepted the BLA for [vic-]trastuzumab duocarmazine to treat HER2-positive unresectable locally advanced or metastatic breast cancer.
Source: empr.com
![FDA to Review [Vic-]Trastuzumab Duocarmazine for HER2-Positive BRCA - Vimarsana News](https://vimarsana.com/images/vimarsana-bigimage.jpg)
Page 2 - Jan Schellens News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Jan Schellens. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Jan Schellens Today - Breaking & Trending Today
Dutch biotech seeks out industry alliances to commercialize its ADC on back of trial results
Dutch biotech, Byondis, today announced positive topline results from a Phase 3 study, which it says confirms the safety and efficacy of its antibody drug conjugate (ADC) - SYD985 - as a treatment for patients with pretreated HER2-positive locally advanced or metastatic breast cancer (MBC).
Source: outsourcing-pharma.com